Beijing’s insistence that Meta unwind its deal with a Chinese A.I. start-up escalates the geopolitical fight over advanced ...

Targeting LAG-3 and TIGIT did not improve efficacy compared with enfortumab vedotin plus pembrolizumab in advanced urothelial cancer. In patients with locally advanced or metastatic urothelial cancer, ...

Add Yahoo as a preferred source to see more of our stories on Google. When you buy through links on our articles, Future and its syndication partners may earn a commission. Credit: Warner Bros. There ...

This is a syndicated post stub. Renal and Urology News, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform ...

Investigators sought to determine if adding favezelimab or vibostolimab to enfortumab vedotin/pembrolizumab improved overall response rates in patients with locally advanced or metastatic carcinoma.

This study, officially titled “KEYMAKER-U01 Substudy 01F: A Phase 1b/2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated Participants With Advanced or Metastatic ...

Daiichi Sankyo Company ((DSKYF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

Daiichi Sankyo Company ((DSKYF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

Belzutifan, pembrolizumab, and lenvatinib combination showed improved efficacy in advanced ccRCC compared with other regimens. Arm 4 demonstrated a significant median duration of response and ...

Results from sub-study 03A of KEYMAKER-U03, an international, open-label, rolling-arm, phase I/II umbrella trial, spotlight the promise of pembrolizumab-based regimens combined with tyrosine kinase ...

Keanu Reeves is among the most bankable actors in Hollywood, with back-to-back critical and commercial hits in his resume. The fan-favorite actor has never hesitated to embrace a wide variety of roles ...